CytoSolv is a newly formed Rhode Island biomedical company, developing proprietary technology to address wound healing, initially targeting diabetic ulcers. Its technology involves the delivery of a mixture of wound-healing factors derived from porcine choroid plexus (CP) cells cultured using proprietary techniques. These cells normally secrete a variety of factors into the cerebrospinal fluid that are responsible for growth, differentiation, nurturing and maintenance of the brain.
CytoSolv has demonstrated that a topical gel based on a cocktail of these factors accelerates and improves the quality of healing of open skin wounds. It has recently been awarded $500,000 from the Slater Technology Fund to pursue more advanced pre-clinical development in the year ahead.
Paul Tan, chief executive officer of LCT, said: “Although this collaboration is outside LCT’s core business of live cell implants, the topical use of secreted products from porcine CP cells offers a potential revenue stream from supply of cells and investment return. The experienced team at CytoSolv has produced very promising preliminary data, and we look forward to continuing this exciting collaboration.”